USC researchers launch clinical trial for early breast cancer blood test

Researchers at the USC Norris Comprehensive Cancer Center have initiated a clinical trial to evaluate an innovative liquid biopsy designed to detect breast cancer at its earliest stages. The test, developed at the USC Michelson Center Convergent Science Institute, aims to complement traditional mammography by identifying rare cancer-associated cells and tumor-associated large extracellular vesicles (L-EVs) in the bloodstream.

Currently, mammograms are the primary screening tool, but abnormal findings often necessitate additional imaging, biopsies, or follow-up appointments months later. This process can cause significant patient anxiety and potential delays in treatment. The new test seeks to provide more immediate information during stages when the disease is most treatable.

If proven effective, the blood test could also improve healthcare access for populations facing barriers to traditional mammography, such as individuals living in remote areas with limited screening services.